Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 4/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MYOC | Q99972 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683306 | 0.90 | PNLIP (0.50) | PNLIPFFAR1PGRCRHBPCRHR2 | |
| SCHEMBL27676843 | 0.76 | MEN1 (0.74) | PNLIPFFAR1CRHBPCRHR2STK39 | |
| SCHEMBL4350025 | 0.72 | MEN1 (0.59) | PNLIPFFAR1SIRT6MEN1KMT2A | |
| SCHEMBL31315570 | 0.72 | FFAR1 (0.80) | FFAR1PGRCRHBPCRHR2MEN1 | |
| SCHEMBL8306391 | 0.72 | FFAR1 (0.65) | FFAR1PGRCRHBPCRHR2SIRT6 | |
| SCHEMBL27676573 | 0.72 | FFAR1 (0.80) | FFAR1PGRCRHBPCRHR2MEN1 | |
| SCHEMBL6691053 | 0.72 | MEN1 (0.61) | PNLIPFFAR1MEN1KMT2ANPC1 | |
| SCHEMBL9245480 | 0.71 | GAA (0.69) | PNLIPPGRCRHBPCRHR2MEN1 | |
| SCHEMBL31700852 | 0.71 | MEN1 (0.74) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL16677982 | 0.71 | PGR (0.83) | PNLIPFFAR1PGRSTK39MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4032897-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-2970357-B1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-2604620-B9 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| EP-2604620-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | disclosed |
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | disclosed |
| US-7816339-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816339-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100119483-A1 | PEPTIDE VIRAL ENTRY INHIBITORS | SCHERING CORPORATION | 2010-05-13 | — | — | US | disclosed |
| US-20100119483-A1 | PEPTIDE VIRAL ENTRY INHIBITORS | SCHERING CORPORATION | 2010-05-13 | — | — | US | disclosed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-7524831-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524831-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | PNLIP 742/4885FFAR1 2768/4885PGR 3760/4885 |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | PNLIP 742/4885FFAR1 2768/4885PGR 3760/4885 |
| US-20100119483-A1 | PEPTIDE VIRAL ENTRY INHIBITORS | HAVCR2, VIP, TAP1 | PNLIP 851/4885FFAR1 3098/4885PGR 2400/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PNLIP 2985/4885FFAR1 4351/4885PGR 946/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PNLIP 2985/4885FFAR1 4351/4885PGR 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.